---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-029689"
form_type: "8-K"
ticker: "PCSC"
cik: "0002017526"
company_name: "Perceptive Capital Solutions Corp"
filed_at: "2026-07-27T12:10:47+00:00"
generated_at: "2026-07-27T12:15:08.011216+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves Freenome's SimpleScreen CRC blood test; Abbott to commercialize, $100M milestone payment triggered

## Summary
- SimpleScreen CRC detected colorectal cancer with 81.1% sensitivity and 90.4% specificity in the PREEMPT CRC study of over 48,000 patients.
- Freenome receives a $100 million milestone payment from Abbott for FDA approval; Abbott will exclusively commercialize the test in the U.S.
- Test meets Medicare coverage criteria and is expected to be incorporated into American Cancer Society guidelines by name.
- Up to 60 million Americans are overdue for colorectal cancer screening; blood-based test aims to increase screening rates.
- Approval marks first commercial milestone for Freenome's Personalized Cancer Detection platform; company plans to expand SimpleScreen portfolio.

## SEC filing metadata
- accession: 0001140361-26-029689
- form_type: 8-K
- ticker: PCSC
- cik: 0002017526
- company_name: Perceptive Capital Solutions Corp
- filed_at: 2026-07-27T12:10:47+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2017526/000114036126029689/0001140361-26-029689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2017526/000114036126029689/ef20078829_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-029689
- JSON: https://secwatch.observer/filing/0001140361-26-029689.json
- Plain text: https://secwatch.observer/filing/0001140361-26-029689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.